Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Hum Mutat ; 42(1): 89-101, 2021 01.
Article in English | MEDLINE | ID: mdl-33252156

ABSTRACT

Skeletal dysplasias are a heterogeneous group of disorders ranging from mild to lethal skeletal defects. We investigated two unrelated families with individuals presenting with a severe skeletal disorder. In family NMD02, affected individuals had a dysostosis multiplex-like skeletal dysplasia and severe short stature (<-8.5 SD). They manifested increasingly coarse facial features, protruding abdomens, and progressive skeletal changes, reminiscent of mucopolysaccharidosis. The patients gradually lost mobility and the two oldest affected individuals died in their twenties. The affected child in family ID01 had coarse facial features and severe skeletal dysplasia with clinical features similar to mucopolysaccharidosis. She had short stature, craniosynostosis, kyphoscoliosis, and hip-joint subluxation. She died at the age of 5 years. Whole-exome sequencing identified two homozygous variants c.133C>T; p.(Arg45Trp) and c.215dupA; p.(Tyr72Ter), respectively, in the two families, affecting an evolutionary conserved gene TMEM251 (NM_001098621.1). Immunofluorescence and confocal studies using human osteosarcoma cells indicated that TMEM251 is localized to the Golgi complex. However, p.Arg45Trp mutant TMEM251 protein was targeted less efficiently and the localization was punctate. Tmem251 knockdown by small interfering RNA induced dedifferentiation of rat primary chondrocytes. Our work implicates TMEM251 in the pathogenesis of a novel disorder and suggests its potential function in chondrocyte differentiation.


Subject(s)
Dwarfism , Membrane Proteins , Osteochondrodysplasias , Animals , Female , Humans , Rats , Dwarfism/genetics , Exome Sequencing , Homozygote , Membrane Proteins/genetics , Osteochondrodysplasias/genetics , Pedigree
2.
J Inherit Metab Dis ; 43(4): 871-879, 2020 07.
Article in English | MEDLINE | ID: mdl-32049367

ABSTRACT

Pathogenic variants in the Golgi localised alpha 1,6 fucosyltransferase, FUT8, cause a rare inherited metabolic disorder known as FUT8-CDG. To date, only three affected individuals have been reported presenting with a constellation of symptoms including intrauterine growth restriction, severe delays in growth and development, other neurological impairments, significantly shortened limbs, respiratory complications, and shortened lifespan. Here, we report an additional four unrelated affected individuals homozygous for novel pathogenic variants in FUT8. Analysis of serum N-glycans revealed a complete lack of core fucosylation, an important diagnostic biomarker of FUT8-CDG. Our data expands both the molecular and clinical phenotypes of FUT8-CDG and highlights the importance of identifying a reliable biomarker for confirming potentially pathogenic variants.


Subject(s)
Congenital Disorders of Glycosylation/genetics , Fucose/metabolism , Fucosyltransferases/genetics , Polysaccharides/metabolism , Congenital Disorders of Glycosylation/metabolism , Female , Fucosyltransferases/deficiency , Humans , Male , Mass Spectrometry , Phenotype , Exome Sequencing
3.
Mol Cell Neurosci ; 85: 183-189, 2017 12.
Article in English | MEDLINE | ID: mdl-29055697

ABSTRACT

Natural antisense transcripts (NATs) are an abundant class of long noncoding RNAs that have recently been shown to be key regulators of chromatin dynamics and gene expression in nervous system development and neurological disorders. However, it is currently unclear if NAT-based mechanisms also play a role in drug-induced neuroadaptations. Aberrant regulation of gene expression is one critical factor underlying the long-lasting behavioral abnormalities that characterize substance use disorder, and it is possible that some drug-induced transcriptional responses are mediated, in part, by perturbations in NAT activity. To test this hypothesis, we used an automated algorithm that mines the NCBI AceView transcriptomics database to identify NAT overlapping genes linked to addiction. We found that 22% of the genes examined contain NATs and that expression of Homer1 natural antisense transcript (Homer1-AS) was altered in the nucleus accumbens (NAc) of mice 2h and 10days following repeated cocaine administration. In in vitro studies, depletion of Homer1-AS lead to an increase in the corresponding sense gene expression, indicating a potential regulatory mechanisms of Homer1 expression by its corresponding antisense transcript. Future in vivo studies are needed to definitely determine a role for Homer1-AS in cocaine-induced behavioral and molecular adaptations.


Subject(s)
Cocaine/pharmacology , Dopamine Uptake Inhibitors/pharmacology , Gene Expression Regulation/drug effects , Homer Scaffolding Proteins/drug effects , Nucleus Accumbens/drug effects , RNA, Antisense/biosynthesis , Animals , Gene Expression Regulation/genetics , Homer Scaffolding Proteins/metabolism , Male , Mice , Mice, Inbred C57BL , RNA, Antisense/drug effects
4.
JCI Insight ; 2(6): e91782, 2017 03 23.
Article in English | MEDLINE | ID: mdl-28352664

ABSTRACT

Molecular mechanisms underlying learning and memory remain imprecisely understood, and restorative interventions are lacking. We report that intranasal administration of siRNAs can be used to identify targets important in cognitive processes and to improve genetically impaired learning and memory. In mice modeling the intellectual deficiency of Fragile X syndrome, intranasally administered siRNA targeting glycogen synthase kinase-3ß (GSK3ß), histone deacetylase-1 (HDAC1), HDAC2, or HDAC3 diminished cognitive impairments. In WT mice, intranasally administered brain-derived neurotrophic factor (BDNF) siRNA or HDAC4 siRNA impaired learning and memory, which was partially due to reduced insulin-like growth factor-2 (IGF2) levels because the BDNF siRNA- or HDAC4 siRNA-induced cognitive impairments were ameliorated by intranasal IGF2 administration. In Fmr1-/- mice, hippocampal IGF2 was deficient, and learning and memory impairments were ameliorated by IGF2 intranasal administration. Therefore intranasal siRNA administration is an effective means to identify mechanisms regulating cognition and to modulate therapeutic targets.


Subject(s)
Cognition Disorders/genetics , Fragile X Syndrome/genetics , Insulin-Like Growth Factor II/genetics , RNA, Small Interfering/administration & dosage , Administration, Intranasal , Animals , Cognition Disorders/psychology , Fragile X Mental Retardation Protein/genetics , Fragile X Syndrome/psychology , Glycogen Synthase Kinase 3 beta/genetics , Histone Deacetylases/genetics , Mice , Mice, Knockout
5.
World J Biol Psychiatry ; 18(6): 445-456, 2017 09.
Article in English | MEDLINE | ID: mdl-27723376

ABSTRACT

OBJECTIVES: We examined mechanisms that contribute to the rapid antidepressant effect of ketamine in mice that is dependent on glycogen synthase kinase-3 (GSK3) inhibition. METHODS: We measured serotonergic (5HT)-2C-receptor (5HTR2C) cluster microRNA (miRNA) levels in mouse hippocampus after administering an antidepressant dose of ketamine (10 mg/kg) in wild-type and GSK3 knockin mice, after GSK3 inhibition with L803-mts, and in learned helpless mice. RESULTS: Ketamine up-regulated cluster miRNAs 448-3p, 764-5p, 1264-3p, 1298-5p and 1912-3p (2- to 11-fold). This up-regulation was abolished in GSK3 knockin mice that express mutant constitutively active GSK3. The GSK3 specific inhibitor L803-mts was antidepressant in the learned helplessness and novelty suppressed feeding depression-like behaviours and up-regulated the 5HTR2C miRNA cluster in mouse hippocampus. After administration of the learned helplessness paradigm mice were divided into cohorts that were resilient (non-depressed) or were susceptible (depressed) to learned helplessness. The resilient, but not depressed, mice displayed increased hippocampal levels of miRNAs 448-3p and 1264-3p. Administration of an antagonist to miRNA 448-3p diminished the antidepressant effect of ketamine in the learned helplessness paradigm, indicating that up-regulation of miRNA 448-3p provides an antidepressant action. CONCLUSIONS: These findings identify a new outcome of GSK3 inhibition by ketamine that may contribute to antidepressant effects.


Subject(s)
Antidepressive Agents/pharmacology , Behavior, Animal/drug effects , Glycogen Synthase Kinase 3/antagonists & inhibitors , Hippocampus/drug effects , Hippocampus/metabolism , Introns/drug effects , Ketamine/pharmacology , MicroRNAs/drug effects , Protein Kinase Inhibitors/pharmacology , Receptor, Serotonin, 5-HT2C/drug effects , Animals , Antidepressive Agents/administration & dosage , Depression/drug therapy , Disease Models, Animal , Helplessness, Learned , Ketamine/administration & dosage , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Oligopeptides/administration & dosage , Oligopeptides/pharmacology , Protein Kinase Inhibitors/administration & dosage , Up-Regulation
6.
Cell Rep ; 7(5): 1401-1409, 2014 Jun 12.
Article in English | MEDLINE | ID: mdl-24857657

ABSTRACT

The primarily neuronal RNA-binding protein HuD is implicated in learning and memory. Here, we report the identification of several HuD target transcripts linked to Alzheimer's disease (AD) pathogenesis. HuD interacted with the 3' UTRs of APP mRNA (encoding amyloid precursor protein) and BACE1 mRNA (encoding ß-site APP-cleaving enzyme 1) and increased the half-lives of these mRNAs. HuD also associated with and stabilized the long noncoding (lnc)RNA BACE1AS, which partly complements BACE1 mRNA and enhances BACE1 expression. Consistent with HuD promoting production of APP and APP-cleaving enzyme, the levels of APP, BACE1, BACE1AS, and Aß were higher in the brain of HuD-overexpressing mice. Importantly, cortex (superior temporal gyrus) from patients with AD displayed significantly higher levels of HuD and, accordingly, elevated APP, BACE1, BACE1AS, and Aß than did cortical tissue from healthy age-matched individuals. We propose that HuD jointly promotes the production of APP and the cleavage of its amyloidogenic fragment, Aß.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , ELAV Proteins/metabolism , RNA, Long Noncoding/metabolism , 3' Untranslated Regions , Aged , Aged, 80 and over , Amyloid Precursor Protein Secretases/genetics , Amyloid Precursor Protein Secretases/metabolism , Animals , Aspartic Acid Endopeptidases/genetics , Aspartic Acid Endopeptidases/metabolism , Case-Control Studies , Cell Line, Tumor , Cerebral Cortex/metabolism , ELAV Proteins/genetics , Female , Humans , Male , Mice , Mice, Inbred C57BL , Middle Aged , RNA Stability , RNA, Long Noncoding/genetics
7.
Nat Biotechnol ; 26(8): 933-40, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18641635

ABSTRACT

Small interfering RNAs (siRNAs) and microRNAs (miRNAs) are sequence-specific post-transcriptional regulators of gene expression. Although major components of the RNA interference (RNAi) pathway have been identified, regulatory mechanisms for this pathway remain largely unknown. Here we demonstrate that the RNAi pathway can be modulated intracellularly by small molecules. We have developed a cell-based assay to monitor the activity of the RNAi pathway and find that the small-molecule enoxacin (Penetrex) enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. We show that this RNAi-enhancing activity depends on the trans-activation-responsive region RNA-binding protein. Our results provide a proof-of-principle demonstration that small molecules can be used to modulate the activity of the RNAi pathway. RNAi enhancers may be useful in the development of research tools and therapeutics.


Subject(s)
Enoxacin/pharmacology , MicroRNAs/genetics , RNA Interference/drug effects , RNA Processing, Post-Transcriptional , RNA, Small Interfering/genetics , Animals , Cell Line , Genes, Reporter , Genetic Vectors , Green Fluorescent Proteins/metabolism , Humans , Lentivirus/genetics , Mice , Mice, Transgenic , MicroRNAs/metabolism , RNA, Small Interfering/drug effects , RNA, Small Interfering/metabolism , RNA-Binding Proteins/metabolism , RNA-Induced Silencing Complex/metabolism , Transfection
8.
BMC Genomics ; 8: 74, 2007 Mar 15.
Article in English | MEDLINE | ID: mdl-17362513

ABSTRACT

BACKGROUND: Mutations in the PTEN induced putative kinase 1 (PINK1) are implicated in early-onset Parkinson's disease. PINK1 is expressed abundantly in mitochondria rich tissues, such as skeletal muscle, where it plays a critical role determining mitochondrial structural integrity in Drosophila. RESULTS: Herein we characterize a novel splice variant of PINK1 (svPINK1) that is homologous to the C-terminus regulatory domain of the protein kinase. Naturally occurring non-coding antisense provides sophisticated mechanisms for diversifying genomes and we describe a human specific non-coding antisense expressed at the PINK1 locus (naPINK1). We further demonstrate that PINK1 varies in vivo when human skeletal muscle mitochondrial content is enhanced, supporting the idea that PINK1 has a physiological role in mitochondrion. The observation of concordant regulation of svPINK1 and naPINK1 during in vivo mitochondrial biogenesis was confirmed using RNAi, where selective targeting of naPINK1 results in loss of the PINK1 splice variant in neuronal cell lines. CONCLUSION: Our data presents the first direct observation that a mammalian non-coding antisense molecule can positively influence the abundance of a cis-transcribed mRNA under physiological abundance conditions. While our analysis implies a possible human specific and dsRNA-mediated mechanism for stabilizing the expression of svPINK1, it also points to a broader genomic strategy for regulating a human disease locus and increases the complexity through which alterations in the regulation of the PINK1 locus could occur.


Subject(s)
Gene Expression Regulation , Mitochondria/physiology , Protein Kinases/genetics , RNA, Antisense/physiology , Cell Line , Humans , Muscle, Skeletal , Neurons , Parkinson Disease/genetics , Protein Isoforms , RNA, Double-Stranded , RNA, Messenger
9.
BMC Genomics ; 6: 18, 2005 Feb 17.
Article in English | MEDLINE | ID: mdl-15717931

ABSTRACT

BACKGROUND: Over 4 million single nucleotide polymorphisms (SNPs) are currently reported to exist within the human genome. Only a small fraction of these SNPs alter gene function or expression, and therefore might be associated with a cell phenotype. These functional SNPs are consequently important in understanding human health. Information related to functional SNPs in candidate disease genes is critical for cost effective genetic association studies, which attempt to understand the genetics of complex diseases like diabetes, Alzheimer's, etc. Robust methods for the identification of functional SNPs are therefore crucial. We report one such experimental approach. RESULTS: Sequence conserved between mouse and human genomes, within 5 kilobases of the 5-prime end of 176 GPCR genes, were screened for SNPs. Sequences flanking these SNPs were scored for transcription factor binding sites. Allelic pairs resulting in a significant score difference were predicted to influence the binding of transcription factors (TFs). Ten such SNPs were selected for mobility shift assays (EMSA), resulting in 7 of them exhibiting a reproducible shift. The full-length promoter regions with 4 of the 7 SNPs were cloned in a Luciferase based plasmid reporter system. Two out of the 4 SNPs exhibited differential promoter activity in several human cell lines. CONCLUSIONS: We propose a method for effective selection of functional, regulatory SNPs that are located in evolutionary conserved 5-prime flanking regions (5'-FR) regions of human genes and influence the activity of the transcriptional regulatory region. Some SNPs behave differently in different cell types.


Subject(s)
Gene Expression Regulation , Genome, Human , Polymorphism, Single Nucleotide , Sequence Analysis, DNA/methods , Algorithms , Alleles , Animals , Binding Sites , Cell Line , Chromosome Mapping , Conserved Sequence , Evolution, Molecular , Humans , Luciferases/metabolism , Mice , Models, Genetic , Molecular Sequence Data , Oligonucleotides/chemistry , Phenotype , Plasmids/metabolism , Polymorphism, Restriction Fragment Length , Promoter Regions, Genetic , Protein Binding , Transcription Factors/metabolism , Transcription, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...